azd6482 + acetylsalicylic acid

**azd6482 + acetylsalicylic acid** is an investigational combination of a selective phosphoinositide 3-kinase beta (PI3Kβ) inhibitor (AZD6482) and acetylsalicylic acid, commonly known as aspirin. AZD6482 is a small molecule that selectively inhibits PI3Kβ, a crucial enzyme in the PI3K-AKT signaling pathway involved in platelet activation, tumor proliferation, and survival. Acetylsalicylic acid is a widely used nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase-1 (COX-1), thereby suppressing thromboxane A2-mediated platelet aggregation. This combination has been studied primarily for its potential as an antiplatelet regimen: preclinical and early clinical studies in healthy volunteers have shown that dual therapy with AZD6482 and acetylsalicylic acid produced greater antiplatelet efficacy with less bleeding risk compared to standard clopidogrel plus aspirin therapy. The combination is not currently approved for any indication and is undergoing early-phase clinical investigation as an alternative dual antiplatelet therapy, potentially offering improved safety and efficacy profiles for cardiovascular and thrombotic disease prevention[3][5][7].

Other names

aspirinASA